Why CRISPR Therapeutics Stock Fell 18.4% in October
Shares of CRISPR Therapeutics (NASDAQ: CRSP) slid 18.4% in October, according to data from S&P Global Market Intelligence. The biotech stock lost ground after the company published weaker-than-expected trial results for one of its key clinical therapies.
Source Fool.com